US equities |
AAPL $331.81 ▼-1.93% MU $850.97 ▲+2.08% NVDA $207.00 ▲+2.45% AMD $487.16 ▲+4.35% SPCX $141.69 ▲+3.90% PLTR $174.78 ▼-1.99% ORCL $124.73 ▲+4.62% TSLA $399.00 ▼-1.19%
FinancialContent

Cerus Corporation - Common Stock (NQ:CERS)

2.365 +0.005 (+0.21%)
Delayed Quote Updated: 2:41 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cerus Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Cerus: 3 Key Takeaways for Long-Term Investors ↗
A shift to higher-margin kit distribution and a successful red blood cell trial position Cerus for path to GAAP profitability. 
Via The Motley Fool
Topics Earnings
News headline image
Cerus (CERS) Q3 2026 Earnings Call Transcript ↗
REDeS trial met efficacy endpoints; ISC revenue surged 44% year over year. 
Via The Motley Fool
Topics Earnings
News headline image
Cerus Q3 Earnings Call Highlights ↗
Cerus (NASDAQ:CERS) reported third-quarter product revenue growth of 10% year over year and reaffirmed its 2026 revenue outlook, while also announcing positive top-line results from its Phase III RedeS... 
Via MarketBeat
Topics Earnings
Cerus Corp (NASDAQ:CERS) Posts In-Line Q3 Revenue and Positive RedeS Data ↗
Via Chartmill
Cerus Corp (NASDAQ:CERS) Drops 10% After Q2 Revenue Beat Overshadowed by Lowered Full-Year Guidance ↗
Via Chartmill
Cerus Corp (NASDAQ:CERS) Surges on Strong Q1 Beat and Raised Guidance ↗
Via Chartmill
Cerus Corp (NASDAQ:CERS) Reports Mixed Q4 2025 Results, Stock Falls on Revenue Miss ↗
Via Chartmill
News headline image
Cerus Corporation Announces Third Quarter 2026 Financial Results
From Cerus Corporation
Via Business Wire
News headline image
Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial of the INTERCEPT Blood System for Red Blood Cells
From Cerus Corporation
Via Business Wire
News headline image
Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026
From Cerus Corporation
Via Business Wire
News headline image
Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting
From Cerus Corporation
Via Business Wire
News headline image
Cerus Q2 Earnings Call Highlights ↗
Cerus (NASDAQ:CERS) reported second-quarter product revenue growth of 10% year over year and raised the low end of its 2026 product revenue outlook, citing demand for its INTERCEPT blood-safety... 
Via MarketBeat
Topics Earnings
News headline image
Cerus Corporation Announces Second Quarter 2026 Financial Results
From Cerus Corporation
Via Business Wire
News headline image
Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026
From Cerus Corporation
Via Business Wire
News headline image
Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress
From Cerus Corporation
Via Business Wire
News headline image
Cerus Corporation Closes New Debt Facility of Up to $110 Million
From Cerus Corporation
Via Business Wire
Which stocks are moving on Friday? ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Cerus (CERS) Q1 2026 Earnings Transcript ↗
Cerus (CERS) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Economy World Trade
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
News headline image
Cerus Corporation Announces First Quarter 2026 Financial Results
From Cerus Corporation
Via Business Wire
News headline image
Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System
From Cerus Corporation
Via Business Wire
News headline image
Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026
From Cerus Corporation
Via Business Wire
News headline image
Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer
From Cerus Corporation
Via Business Wire
News headline image
Cerus (CERS) Q4 2025 Earnings Call Transcript ↗
Cerus (CERS) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings World Trade
News headline image
Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results
From Cerus Corporation
Via Business Wire
News headline image
Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference
From Cerus Corporation
Via Business Wire
News headline image
Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026
From Cerus Corporation
Via Business Wire
News headline image
DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus’ INTERCEPT™ Blood System in Routine Clinical Practice
From Cerus Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >